MRNA

Moderna Stock Price

383.25
-25.59 (-6.26%)
383.25

Low
65.4899

52 Week Range

High
497.17

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Moderna Inc MRNA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-25.59 -6.26% 383.25 19:41:16
Open Price Low Price High Price Close Price Prev Close
399.77 376.03 403.2957 384.21 408.84
Bid Price Ask Price Spread News
383.25 383.50 0.25 1 1
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
291,818 15,928,390 $ 387.31 $ 6,169,183,795 - 65.4899 - 497.17
Last Trade Time Type Quantity Stock Price Currency
19:42:55 1 $ 383.26 USD

Period:

Draw Mode:

Moderna Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 154.70B 403.65M 295.52M $ 803.40M $ 400.01M -1.95 55.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -674.27k 5.80%

more financials information »

Moderna News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MRNA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week424.30458.50376.03431.6710,843,640-41.05-9.67%
1 Month375.96464.85370.50427.2813,594,6347.291.94%
3 Months229.09497.17214.07375.8519,068,913154.1667.29%
6 Months130.11497.17117.3411303.2113,923,942253.14194.56%
1 Year69.53497.1765.4899209.2115,097,118313.72451.2%
3 Years22.00497.1711.54131.7510,652,970361.251,642.05%
5 Years22.00497.1711.54131.7510,652,970361.251,642.05%

Moderna Description

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.


Your Recent History
NASDAQ
MRNA
Moderna
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.